JP2018008893A - Hyperglycemia inhibitor - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide an agent capable of exhibiting hyperglycemia-inhibiting action or a composition comprising the same.SOLUTION: According to the present invention, there is provided a hyperglycemia inhibitor comprising as an active component at least one selected from the group consisting of a fucoxanthinol-containing egg, at least a part thereof, and a processed product thereof. According to the present invention, there is also provided a food composition for inhibiting hyperglycemia, the composition comprising the hyperglycemia inhibitor.SELECTED DRAWING: None

Description

  The present invention relates to a hyperglycemia inhibitor.

  The number of diabetic patients in Japan is estimated to be about 8.9 million, the number of diabetic reserves is estimated to be about 13.2 million, and the number is increasing year by year. Japanese have a predisposition to become diabetic, that is, a constitution that makes it difficult to consume and store food, and the generative gene possession rate is said to be 2-5 times that of Westerners. Since diabetes is a significant risk factor for arteriosclerotic diseases, establishment of prevention and treatment methods has become a serious issue.

  Currently, as therapeutic agents for diabetes, sulfonylurea agents (SU agents) that promote insulin secretion, phenylalanine derivatives, α-glycosidase inhibitors that suppress sugar absorption, and biquanides (BG that suppress sugar production in the liver) ) Drugs and thiazolidine derivatives that improve insulin resistance are known. Diabetes is not completely curable and patients with diabetes have to continue to use these medicines, so the burden on the patient is very high. In addition, these drugs are prescribed only when diagnosed with diabetes, and those who belong to the diabetic reserve arm have no choice but to rely on diet therapy and exercise therapy. For these reasons, development of a technique capable of preventing or improving the onset of diabetes without greatly changing daily life is eagerly desired.

  Fucoxanthin is a kind of carotenoid that is contained in a high concentration in seaweeds such as dry algae and microalgae. Fucoxanthin-containing dry algae extract significantly improves hyperglycemia with significant weight loss in humans and, as a mechanism of action, fucoxanthin-containing brown algae extract significantly increases energy consumption (Non-Patent Document 1). It has also been reported that studies with cells and animals have revealed that fucoxanthin increases GLUT4 membrane translocation that promotes sugar uptake in muscle cells and tissues (Patent Document 1, Non-Patent Document 1). Reference 2). On the other hand, it is reported that about 70 to 80% of fucoxanthin is converted to fucoxanthinol at the time of absorption, and the main active body of fucoxanthin's hyperglycemic inhibitory action is considered to be fucoxanthinol. (Non-Patent Documents 3 and 4). Based on such a background, an anti-obesity active agent using fucoxanthinol and a method for suppressing obesity have already been reported (Patent Document 2).

  It is desired that the improvement of the hyperglycemic state due to diabetes is not transient but fundamental including the constitution. Excess glucose taken into the body is taken into the liver and muscles from the blood and stored as glycogen. If this glucose uptake can be promoted, it is considered that the hyperglycemic state can be improved. Since 70% or more of the glucose metabolism is performed in muscles, improvement of hyperglycemia can be expected by promoting glucose uptake into muscles.

  Non-Patent Document 5 describes that fucoxanthinol was detected in egg yolk when a chicken was fed with a seaweed lipid containing fucoxanthin.

Japanese Patent No. 5099812 Japanese Patent No. 5012505

Abidov M et al. Diabetes Obes Metab (2010) 12, 72-81. Nishikawa S et al. Phytomedicine (2012) 19, 389-394. Hosokawa M et al. Arch Biochem Biophys (2010) 504, 17-25. Wu FC et al. J Nutr (2002) 132, 72-81. News from Kitamizu trial (2009) 77, 22-25.

  However, fucoxanthin and fucoxanthinol are difficult to formulate because they are fat-soluble substances, and there has been a problem in using them for various purposes. In addition, the use of chicken eggs containing fucoxanthinol has not been known. An object of this invention is to provide the agent which can fully exhibit the hyperglycemia suppression effect of fucoxanthinol in the body.

  The present inventors obtained fucoxanthinol-containing egg yolk powder by causing fucoxanthin or fucoxanthinol-containing sample to ingest chickens so that fucoxanthinol was accumulated in the egg yolk. For the evaluation of functional food components, animals, particularly rodents, are generally used, and the effectiveness of fucoxanthin and fucoxanthinol is also evaluated in animals. Fucoxanthin is the lowest concentration at which 0.05% concentration in the sample has been reported to be effective for hyperglycemia, and for fucoxanthinol, the 0.2% concentration is the lowest. This is the lower limit (Non-patent Document 5, Patent Document 2). As a result of diligent investigation using the produced egg yolk powder with reference to the above-mentioned literature, the present inventors surprisingly found that fucoxanthinol-containing eggs have been known to date. It was found that hyperglycemia was suppressed even at a dose much lower than the ingested dose that exerted the effect of coxanthinol.

The present invention provides the following [1] to [5].
[1] A hyperglycemia inhibitor comprising fucoxanthinol-containing egg yolk powder as an active ingredient.
[2] A hyperglycemia inhibitor comprising fucoxanthinol-containing egg yolk oil as an active ingredient.
[3] A hyperglycemia inhibitor comprising a fucoxanthinol-containing raw egg as an active ingredient.
[4] A hyperglycemia inhibitor comprising fucoxanthinol-containing egg yolk as an active ingredient.
[5] A food composition for suppressing hyperglycemia, comprising the agent according to any one of [1] to [4].

  ADVANTAGE OF THE INVENTION According to this invention, the hyperglycemia inhibitor which can exhibit a favorable hyperglycemia suppression effect is provided.

  In the present invention, the fucoxanthinol-containing egg is an egg containing fucoxanthinol transferred from the bird's body. When the fucoxanthinol-containing egg is egg yolk powder, the content of fucoxanthinol in the egg yolk powder is usually 0.01 ppm or more, preferably 0.1 ppm or more, more preferably 1.0 ppm or more, and further preferably 3 ppm. That's it. The upper limit is usually 30 ppm or less, preferably 20 ppm or less, more preferably 9.8 ppm or less.

  Although the manufacturing method of a fucoxanthinol containing egg yolk powder is not specifically limited, For example, the method of manufacturing by pulverizing the yolk of the egg which the bird which ingested fucoxanthin or fucoxanthinol spawned is mentioned.

  The bird is not particularly limited as long as it is a female bird, and examples thereof include poultry such as chicken, turkey, quail, duck, and goose. The age of the bird is not particularly limited, but is not particularly limited as long as it has the ability to lay eggs.

  The method (administration method) for ingesting fucoxanthin or fucoxanthinol to a bird is not particularly limited, and for example, oral administration (for example, oral administration, sublingual administration, etc.), parenteral administration (intravenous administration, muscle) Internal administration, subcutaneous administration, transdermal administration, nasal administration, transpulmonary administration, etc.). Among these, a less invasive dosage form is preferable, and oral administration is usually used.

  The origin of fucoxanthin and fucoxanthinol is not particularly limited, and may be derived from natural products (for example, seaweeds such as dry algae, microalgae), or may be chemically synthesized. In the case of being derived from a natural product, the degree of extraction is not particularly limited, and any of a crude extract, an extract and a purified product may be used.

  In the case of oral administration, fucoxanthin or fucoxanthinol is preferably mixed with the feed. The content of fucoxanthin or fucoxanthinol in the feed is usually 0.0006% by mass or more, preferably 0.003% by mass or more, and more preferably 0.006% by mass or more. The upper limit is usually 0.15% by mass or less, preferably 0.03% by mass or less, and more preferably 0.018% by mass or less.

  The feed may contain other components in addition to fucoxanthin and / or fucoxanthinol. Other components are not particularly limited as long as they are components that are usually contained in avian feed.

  The feed needs only to contain or be able to contain fucoxanthin or fucoxanthinol, and the dosage form is not particularly limited, but liquid (liquid), syrup (syrup), tablet (tablet, tablet), capsule (Capsule, hard capsule), powder (granule, fine particle), soft capsule (soft capsule), usually powder. The feed may contain the components contained in a normal blended feed.

  The daily intake of avian fucoxanthin or fucoxanthinol is not particularly limited because it depends on the intake period, type of bird, health condition, etc., but is usually 0.2 ng / g body weight or more, preferably 0.6 ng / Body weight g or more, more preferably 1.2 ng / body weight g or more. The upper limit is usually 500 ng / body weight g or less, preferably 300 ng / body weight g or less, more preferably 100 ng / body weight g or less.

  The period during which the bird takes fucoxanthin or fucoxanthinol is not particularly limited because it depends on the amount of intake, type of bird, health condition, etc., but is usually 10 days or longer, preferably 20 days or longer, more preferably 29 More than a day. The upper limit is usually 60 days or less, preferably 50 days or less, more preferably 40 days or less.

  In the present invention, the fucoxanthinol-containing egg is used as it is (raw egg), and at least a part (preferably egg yolk) or a fucoxanthinol-containing egg and / or a processed product thereof is used. May be. Examples of the processed product include powder, oil, and solution, and egg yolk powder, egg yolk oil, and egg yolk liquid are preferable. The processing method is not particularly limited. Egg yolk powder can be produced by lyophilization. Egg yolk oil can be produced by heating egg yolk to remove solids. The egg yolk liquid can be produced by adding an appropriate amount of water or saline to the egg yolk.

  A fucoxanthinol-containing egg can exert a hyperglycemia-inhibiting action when ingested by a living body. Daily intake (total amount in the case of a combination of two or more) of fucoxanthinol-containing eggs in an adult is preferably 0.1 g or more, more preferably 0.2 g or more in the case of egg yolk powder. More preferably, it is 0.3 g or more. An upper limit becomes like this. Preferably it is 26 g or less, More preferably, it is 12 g or less, More preferably, it is 5.25 g or less.

  Fucoxanthinol-containing eggs can be used as agents alone or in combination with other components. Since fucoxanthinol-containing eggs have a hyperglycemia-inhibiting action as described above, agents containing fucoxanthinol-containing eggs can be used as hyperglycemia inhibitors. Since the hyperglycemic inhibitory action is useful for the prevention or suppression of diseases such as diabetes, metabolic syndrome, hyperglycemia, impaired glucose tolerance, obesity, etc., the agent of the present invention is also useful as a preventive or inhibitor of these diseases It is.

  The agent of the present invention only needs to contain at least one fucoxanthinol-containing egg, and may contain a combination of two or more fucoxanthinol-containing eggs having different production methods and compositions.

  The agent of this invention should just use the fucoxanthinol containing egg as an active ingredient, and may contain another component as needed. There is no restriction | limiting in particular as long as the effect of this invention is not impaired as another component, For example, the support | carrier accept | permitted pharmacologically is mentioned.

  The pharmacologically acceptable carrier may be appropriately selected depending on the dosage form, and examples thereof include ethanol, water, and starch.

  In the present invention, other components may be contained in addition to the fucoxanthinol-containing egg and the pharmacologically acceptable carrier. Examples of other components include oily components, excipients, disintegrants, binders, lubricants, coating agents, colorants, color formers, flavoring agents, flavoring agents, antioxidants, preservatives, and tastes. Ingredients, sour agents, sweeteners, fortifiers, swelling agents, thickeners, surfactants, fucoxanthinol-containing eggs, and components having antihyperglycemic activity other than pharmacologically acceptable carriers. The optional component may be selected according to the dosage form, type, etc. of the food composition, and may be one type or a combination of two or more types.

  Examples of the oil component include fatty acid esters, hydrocarbons, higher fatty acids, higher alcohols, and the like.

  Examples of the excipient include cellulose such as hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, crystalline cellulose, ethylcellulose, low-substituted hydroxypropylcellulose, and pharmacologically acceptable derivatives thereof, polyvinylpyrrolidone, and partially saponified polyvinyl alcohol. Synthetic polymers such as gelatin, gum arabic powder, pullulan, agar, alginic acid, sodium alginate, chitansan gum and other starches, corn starch, potato starch, pregelatinized starch, hydroxypropyl starch and other pharmacologically acceptable Derivatives, lactose, fructose, glucose, sucrose, trehalose, palatinose, mannitol, sorbitol, erythritol, xylitol, reduced palatinose, powder Based maltose syrup, sugars and sugar alcohols such as maltitol, light anhydrous silicic acid, particulate silicon oxide, particulate silicon dioxide, titanium oxide, and inorganic excipients such as aluminum hydroxide gel. The content of the excipient with respect to the total amount of the agent is preferably 0.01% by mass or more. The upper limit is preferably 70% by mass or less.

  Examples of the disintegrant include crospovidone, carmellose calcium, croscarmellose sodium, low-substituted hydroxypropyl cellulose, carboxymethyl cellulose, carboxymethyl starch sodium, hydroxypropyl starch, and partially pregelatinized starch.

  Examples of the binder include hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, ethylcellulose, polyvinyl alcohol, polyvinylpyrrolidone, gelatin, dextrin, starch, pregelatinized starch and the like.

  Examples of the lubricant include calcium stearate, magnesium stearate, sucrose fatty acid ester, light anhydrous silicic acid, sodium stearyl fumarate, polyethylene glycol, talc, stearic acid and the like. The content of the lubricant with respect to the total amount of the agent is preferably 0.01% by mass or more. The upper limit is preferably 25% by mass or less.

  The dosage form of fucoxanthinol-containing eggs and agents containing the same are not particularly limited. For example, oral administration (eg, oral administration, sublingual administration, etc.), parenteral administration (intravenous administration, intramuscular administration, subcutaneous administration, transdermal administration, nasal administration, pulmonary administration, etc.) and the like can be mentioned. Among these, a less invasive dosage form is preferable, and oral administration (internal use) is more preferable.

  Examples of the dosage form of the oral administration agent (internal use) or the composition for oral administration (composition for internal use) include, for example, liquid (solution), syrup (syrup), tablet (tablet, tablet), capsule (capsule) Agent), powder (granule, fine granule), soft capsule (soft capsule), solid, semi-liquid, cream, and paste.

  The dosage of fucoxanthinol-containing eggs in the preparation may be appropriately determined with reference to the above-mentioned guideline for the intake of fucoxanthinol-containing eggs.

The administration target of the fucoxanthin-containing egg and the agent containing the same may be an animal including a human, and is usually a human. The administration subject may be a healthy person, but is preferably a hyperglycemic person. A person with high blood sugar usually has a fasting blood glucose level of 2) normal high level, 3) border zone, or 4) diabetic zone, and the fasting blood glucose level is 2) normal above. High and 3) Those who are in any of the boundary areas are preferred.
1) Normal region: less than 100 mg / dL 2) Normal high value: 100 mg / dL or more and less than 110 mg / dL 3) Boundary region: 110 mg / dL or more and less than 126 mg / dL 4) Diabetes region: 126 mg / dL or more

  The administration subject may also be a patient with a disease such as diabetes, metabolic syndrome, hyperglycemia, impaired glucose tolerance, obesity and the like.

  Suppressing hyperglycemia refers to suppressing hyperglycemia, relieving hyperglycemia (making blood glucose levels close to normal), preventing hyperglycemia, or normal blood sugar Means to keep the value.

  The subject is not limited to humans, and may be animals other than humans (for example, mammals such as mice, rats, hamsters, dogs, cats, sheep, goats, cows, pigs, monkeys).

  Fucoxanthinol-containing eggs and agents containing them can be used as food compositions, pharmaceuticals, and quasi drugs as they are or in combination with other ingredients. Examples of food compositions include beverages (soft drinks, carbonated drinks, nutritional drinks, powdered drinks, fruit drinks, milk drinks, jelly drinks, etc.), confectionery (cookies, cakes, gums, candies, tablets, gummies, buns, sheep candy) , Pudding, jelly, ice cream, sherbet, etc.), processed fishery products (kamaboko, chikuwa, hanpen, etc.), processed livestock products (hamburg, ham, sausage, winner, cheese, butter, yogurt, fresh cream, cheese, margarine, fermentation Milk, etc.), soup (powder soup, liquid soup, etc.), staple foods (rice, noodles (dried noodles, raw noodles), bread, cereals, etc.), seasonings (mayonnaise, shortening, dressing, sauce, sauce, soy sauce, etc.) ).

  Examples of food compositions include health foods, functional foods, health supplements (supplements), nutritional supplements, foods for specified health use, medical foods, sick foods, infant foods, nursing foods, and elderly use Foods etc. are also mentioned.

  The administration time of the fucoxanthinol-containing egg and the agent containing the same is not particularly limited, but is preferably non-fasting and more preferably after a meal. In general, lipid-based components are more easily absorbed when food is present in the intestinal tract. Therefore, absorption can be promoted when the administration time is the above time.

  Examples of the method for confirming the hyperglycemic inhibitory action of fucoxanthinol-containing eggs and agents containing the same include a method using a hyperglycemic model animal as shown in the Examples. Examples of the method for evaluation using a hyperglycemic model animal include a method of raising a blood glucose level after breeding for a certain period while feeding the hyperglycemic model animal with a diet prepared by mixing a sample with a normal diet. Examples of hyperglycemia model animals include KKAy mice. Commercial products such as CE-2 (Nippon Claire Co., Ltd.) may be used as the normal food. The breeding period of the hyperglycemic model animal is not particularly limited and may be appropriately selected according to the purpose.

  The manufacturing method of the agent containing a fucoxanthinol-containing egg is not particularly limited, and may be manufactured by any method depending on the dosage form, composition, and the like.

  Hereinafter, the present invention will be described in detail with reference to examples. The following examples are for explaining the present invention preferably, and the present invention is not limited to the following examples.

[Production Example 1] Production of fucoxanthinol-containing egg yolk powder The fucoxanthinol-containing egg yolk powder used in the examples was produced by the following procedure.
A 5% fucoxanthin solution (manufactured by Oriza Oil Co., Ltd.) was mixed with chicken food to a concentration of 0.1% and ingested for 4 weeks. The egg yolk of chicken eggs born in the meantime was pulverized according to a standard method. The fucoxanthinol concentration in the egg yolk powder was 6 ppm.

  The concentration of fucoxanthinol in the egg yolk powder was confirmed by high performance liquid chromatography. The measurement conditions were as follows.

  Egg yolk powder (500 mg) was placed in a 15 mL tube, ethanol (5 mL) was added, and the mixture was extracted at room temperature while stirring with a high-speed shaker (Cutemixer, EYELA) for 20 minutes. After centrifugation at 1500 rpm for 5 minutes, the supernatant was collected. The above steps were repeated until the supernatant became transparent (usually 3 times), and the collected supernatant was distilled off.

  The volume was made up to 5 mL with isopropyl alcohol, and high performance liquid chromatography analysis was performed under the following conditions.

HPLC conditions / column: Inertsil ODS-3 (GL Science, 4.6 × 150 mm)
Mobile phase: MeOH / H ₂ O = 85/15, flow rate: 1 mL / min
-Column oven: 40 ° C

[Production Example 2] Production of kombu-derived fucoxanthin Kombu-derived fucoxanthin (FX) used in the comparative example was produced by the following procedure.
1) Extraction process (preparation of crude fucoxanthin)
In a separatory funnel, 500 g of fucoxanthin 1% oil (manufactured by South Product Co., Ltd., derived from Kombu), 500 g of hexane, 500 g of methanol and 50 g of saturated brine are mixed for 1 minute and then allowed to stand for 10 minutes. ) Was recovered. To the remaining upper layer (dark green), 250 g of methanol and 25 g of saturated brine were added and the same operation was performed to recover the lower layer. These recovered lower layers and 250 g of hexane were mixed in a separatory funnel and allowed to stand for 10 minutes, and then the lower layers were recovered and concentrated to dryness with an evaporator to obtain a solid content. The obtained solid content was dissolved in 250 g of diethyl ether, put into a separatory funnel, mixed with 100 g of water, and allowed to stand for 10 minutes. The upper layer (dark red) was collected, dried over sodium sulfate, filtered through filter paper, and the resulting filtrate was concentrated to dryness with an evaporator to obtain crude fucoxanthin (17 g, fucoxanthin purity: 28%, fucoxanthin recovery rate) : 95%). Crude fucoxanthin was subjected to the following two steps.

2) Chromatographic purification process (preparation of purified fucoxanthin)
Crude fucoxanthin (9 g) was dissolved in 50 mL of hexane / acetone = 50/50 (v / v) and purified by silica gel chromatography (φ50 mm × H500 mm). Development started with a hexane / acetone ratio = 70/30 and a final ratio of 50/50. The dark red fractions were collected and concentrated to dryness with an evaporator to obtain purified fucoxanthin (3.5 g, fucoxanthin purity: 65%, fucoxanthin recovery rate: 92%). Purified fucoxanthin was subjected to the following three steps.

3) Recrystallization process (Preparation of high purity fucoxanthin)
Purified fucoxanthin (3.5 g) was dissolved in a minimum amount of acetone, an appropriate amount of water was added, and acetone was distilled off using an evaporator to the extent that crystals did not precipitate. Thereafter, the solution was cooled on ice and allowed to stand until crystals were formed. Suction filtration was performed using hexane as a washing liquid, and the crystals were collected and dried to obtain high-purity fucoxanthin (2 g, fucoxanthin purity: 99%, fucoxanthin recovery rate: 83%).

  The purity of fucoxanthin in the result of each step was confirmed by high performance liquid chromatography under the following conditions.

HPLC conditions / sample: 20 mg was precisely weighed, and 10 μL of a solution obtained by diluting to 50 mL with ethanol was introduced.
Column: Inertsil ODS-3 (5 μm, 4.6 mm (ID) × 150 mm)
-Mobile phase: methanol / water = 85/15 (0 minutes to), 100/0 (8 minutes to), 100/0 (35 minutes to)
・ Flow rate: 1.0 mL / min
・ Oven: 60 ℃
-Detector: UV-VIS (440 nm)

  The recovery rate of fucoxanthin in each step was calculated by the following formula:

  Recovery rate = fucoxanthin weight in the result of each step / fucoxanthin weight in the sample before treatment in each step

  The fucoxanthin weight was calculated by multiplying the weight of the sample by the purity of fucoxanthin measured as described above. In addition, the sample before a process in each refinement | purification process is 1% fucoxanthin oil, crude fucoxanthin, and refined fucoxanthin, respectively.

[Examples 1 and 2]
Using a bait containing 1% and 5% of fucoxanthinol-containing egg yolk powder (Production Example 1) against a commercial bait (trade name: CE-2, manufactured by Clea Japan Co., Ltd.), uniform food intake for all individuals Assuming that the daily intake was 5 g to 5.5 g, hyperglycemia model mice (KKAy mice (CLEA Japan, Inc., 4 weeks old, 7 mice / group) were bred for 16 days (FXnol-containing yolk powder 1 % Group (Example 1), FXnol-containing egg yolk powder 5% group (Example 2)). As a control, a feed containing 5% of egg yolk powder derived from chickens not fed with fucoxanthin in the above-mentioned commercial feed was used (Blank egg yolk powder group). In the bait | mix which mix | blended 1% of FXnol containing egg yolk powder, in order to equalize the compounding quantity as an egg yolk powder between each group, Blank egg yolk powder was mix | blended 4% by weight ratio.

  For each group, the blood glucose level before breeding (before administration, day 0) and the blood glucose level after breeding (16 days after administration) were measured by one-touch ultra (manufactured by Johnson & Johnson Co., Ltd.). The measurement was performed at 10:00 am and the average value was adopted as the blood glucose level of each group. From the ratio of each measured value of each Example when each measured value of the Blank egg yolk powder group was taken as 100%, a reduction rate (%) with respect to each measured value of the Blank egg yolk powder group was calculated (Table 1).

[Comparative Example 1]
Instead of the bait used in the examples, 5% by weight of Blank egg yolk powder was added to the above commercial bait, and a bait added with fucoxanthin (Production Example 2) at a mass ratio of 0.000006% was used. It was. This addition density | concentration was set so that the fucoxanthinol containing density | concentration in a feed might become equivalent to the FXnol containing egg yolk powder 1% group. Other than that, it evaluated similarly to Example 1 (FX0.000006% group, N = 7).

[Comparative Example 2]
Instead of the bait used in the examples, the above-mentioned commercial bait was blended with 5% by weight of Blank egg yolk powder, and fucoxanthinol with a mass ratio of 0.000006% by mass (Wako Pure Chemical, 94% purity) Was used. This addition density | concentration was set so that the fucoxanthinol containing density | concentration in a feed might become equivalent to the FXnol containing egg yolk powder 1% group. Other than that, it evaluated similarly to Example 1 (FXnol 0.000006% group, N = 7).

[Comparative Example 3]
Instead of the bait used in the examples, 5% by weight of Blank egg yolk powder was added to the above commercial bait, and a bait added with fucoxanthin (Production Example 2) at a mass ratio of 0.00003 mass% was used. It was. This addition density | concentration was set so that the fucoxanthinol containing density | concentration in a feed might become equivalent to the FXnol containing egg yolk powder 5% group. Other than that, it evaluated similarly to Example 1 (FX0.00003% group, N = 7).

[Comparative Example 4]
Instead of the bait used in the examples, the above-mentioned commercial bait was blended with 5% by weight of Blank egg yolk powder, and fucoxanthinol with a mass ratio of 0.00003% by mass (Wako Pure Chemical, 94% purity) Was used. This addition density | concentration was set so that the fucoxanthinol containing density | concentration in a feed might become equivalent to the FXnol containing egg yolk powder 5% group. Other than that, it evaluated similarly to Example 1 (FXnol 0.00003% group, N = 7).

  As is clear from Table 1, the blood glucose reduction rate was insufficient in mice ingesting egg yolk powder and fucoxanthin or fucoxanthinol (Comparative Examples 1 to 4), whereas fucoxanthinol-containing egg yolk powder was used. Ingested mice (Examples 1 and 2) showed a high rate of blood glucose reduction. These results indicate that fucoxanthinol-containing eggs have a hyperglycemic inhibitory effect.

Formulation Example 1 (tablet)
Tablets were produced according to a conventional method with the following composition.
Egg yolk powder containing fucoxanthinol 40% by mass
Calcium stearate 5% by mass
Crystalline cellulose 10% by mass
Lactose 43% by mass
Fine silicon dioxide 2% by mass

Formulation example 2 (soft capsule)
Soft capsules were produced according to a conventional method with the following composition.
[Solid formulation / 1 unit]
-Outer layer-
Gelatin ... 130mg
Glycerin ... 70mg
Ethyl paraoxybenzoate 0.5 mg
-Inner layer-
Egg yolk oil containing fucoxanthinol ... 100mg

Claims (5)

  A hyperglycemia inhibitor comprising fucoxanthinol-containing egg yolk powder as an active ingredient.   A hyperglycemia inhibitor comprising fucoxanthinol-containing egg yolk oil as an active ingredient.   An antihyperglycemic agent comprising a fucoxanthinol-containing raw egg as an active ingredient.   A hyperglycemia inhibitor comprising fucoxanthinol-containing egg yolk as an active ingredient.   The food composition for hyperglycemia suppression containing the agent of any one of Claims 1-4.